List of Excipients in Branded Drug ULORIC

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Rebel Distributors Corp	ULORIC	febuxostat	21695-516	CELLULOSE, MICROCRYSTALLINE
Rebel Distributors Corp	ULORIC	febuxostat	21695-516	CROSCARMELLOSE SODIUM
Rebel Distributors Corp	ULORIC	febuxostat	21695-516	HYDROXYPROPYL CELLULOSE
Rebel Distributors Corp	ULORIC	febuxostat	21695-516	LACTOSE MONOHYDRATE
Rebel Distributors Corp	ULORIC	febuxostat	21695-516	MAGNESIUM STEARATE
Rebel Distributors Corp	ULORIC	febuxostat	21695-516	SILICON DIOXIDE
Aphena Pharma Solutions - Tennessee LLC	ULORIC	febuxostat	43353-305	CELLULOSE, MICROCRYSTALLINE

Uloric excipient strategy is commercially relevant because febuxostat is an established, genericized small molecule with a formulation profile that supports cost reduction, patient-experience improvements and selected 505(b)(2) opportunities. The core tablet is relatively simple: lactose, microcrystalline cellulose, croscarmellose sodium, hydroxypropyl cellulose, colloidal silicon dioxide and magnesium stearate, with a conventional film coat. The largest opportunities are lactose-free reformulation, improved dissolution and food-effect control, orally disintegrating or sprinkle products, and differentiated packaging for chronic gout therapy.

Last updated: August 2, 2026

Uloric Febuxostat Excipient Strategy and Commercial Opportunities

What is Uloric and how is febuxostat formulated?

Uloric is the U.S. brand name for febuxostat, a non-purine selective xanthine oxidase inhibitor used to lower serum uric acid in patients with gout. The U.S. Food and Drug Administration approved Uloric tablets in February 2009 under NDA 021856. The marketed strengths are 40 mg and 80 mg immediate-release tablets. The product is administered once daily, with or without food, according to the prescribing information. [1]

Febuxostat is a small molecule rather than a biologic. Biosimilar regulation therefore does not apply. Competition proceeds through generic abbreviated new drug applications, 505(b)(2) applications and, outside the United States, national or centralized generic pathways.

The commercial formulation has a conventional immediate-release architecture:

Formulation element	Uloric function	Commercial relevance
Febuxostat	Active pharmaceutical ingredient	Low daily dose supports compact tablets
Lactose monohydrate	Diluent and tablet-mass builder	Cost-effective but creates lactose-intolerance and excipient-labeling considerations
Microcrystalline cellulose	Filler and compression aid	Supports tablet hardness and manufacturability
Croscarmellose sodium	Superdisintegrant	Promotes rapid tablet breakup
Hydroxypropyl cellulose	Binder	Supports granulation and tablet integrity
Colloidal silicon dioxide	Glidant and moisture-management aid	Improves powder flow and manufacturing consistency
Magnesium stearate	Lubricant	Reduces tablet ejection force; excessive use can slow dissolution
Film-coating system	Protection, appearance and swallowability	Enables strength differentiation and brand recognition

The exact inactive-ingredient composition should be verified against the applicable FDA label and product-specific labeling before a regulatory filing or product development decision. [1]

What excipients does Uloric contain?

The Uloric tablet core uses standard pharmaceutical excipients with broad supplier availability. This reduces manufacturing barriers for generic developers but also limits the ability to obtain meaningful formulation exclusivity from the original composition alone.

The principal excipient strategy is functional rather than novel:

• Lactose monohydrate provides bulk at low cost.
• Microcrystalline cellulose improves compactability and can support direct compression or dry granulation.
• Croscarmellose sodium accelerates disintegration.
• Hydroxypropyl cellulose provides binding capacity.
• Colloidal silicon dioxide improves flow and may reduce segregation.
• Magnesium stearate provides lubrication.
• The film coat supports identification, protection and patient acceptability.

This combination is typical of an immediate-release tablet and is unlikely, by itself, to create a durable patent barrier. A follow-on developer would normally seek a formulation that is pharmaceutically equivalent and bioequivalent, not a duplicate of every inactive ingredient.

Why does lactose matter commercially?

Lactose is inexpensive, widely used and generally acceptable in oral solid dosage forms. It can nevertheless create commercial differentiation opportunities.

A lactose-free febuxostat tablet could target:

• Patients who report lactose intolerance.
• Pharmacies and health systems with excipient restrictions.
• Markets where lactose declaration affects patient or prescriber preference.
• Contract-manufacturing platforms standardized on lactose-free formulations.
• Combination products where total excipient burden is a concern.

The opportunity is commercially meaningful only if the alternative formulation preserves dissolution, stability, tablet hardness and bioequivalence. Replacing lactose with mannitol, dibasic calcium phosphate, anhydrous dibasic calcium phosphate, partially pregelatinized starch or a co-processed filler can change compaction behavior and disintegration.

A lactose-free claim is also vulnerable to commoditization. Once a generic developer demonstrates bioequivalence with a commonly available substitute, the excipient advantage may have limited pricing power unless it is paired with a distinct dosage form, tolerability benefit or channel strategy.

How should an excipient strategy address febuxostat solubility?

Febuxostat is a weakly acidic, poorly water-soluble compound with pH-dependent dissolution characteristics. This makes dissolution control more important than the simple tablet composition may suggest. A formulation can meet immediate-release specifications while still presenting development risks related to particle size, polymorphism, wetting, granulation and lubricant concentration.

Key formulation variables include:

Variable	Potential impact
API particle size	Changes surface area and dissolution rate
API polymorphic form	Can affect solubility, stability and reproducibility
Wetting-agent selection	May improve dissolution but can alter disintegration or stability
Magnesium stearate level	Excessive lubrication can reduce wettability and dissolution
Disintegrant concentration	Controls tablet breakup and release
Granulation method	Affects density, porosity and dissolution
Compression force	Higher force can increase hardness while slowing disintegration
Coating weight	Usually has limited release impact but can affect moisture protection
Microenvironmental pH	May improve dissolution of a weakly acidic API

A developer should avoid treating excipient substitution as a simple cost-reduction exercise. The most defensible product strategy is to define a critical quality attribute package covering assay, content uniformity, dissolution across pH conditions, disintegration, friability, hardness, moisture uptake and accelerated stability.

Are solubilizing excipients commercially attractive?

They can be, but the regulatory and commercial case depends on the intended claim.

Potential approaches include:

• Wetting agents such as sodium lauryl sulfate or poloxamers.
• Hydrophilic polymers such as povidone or copovidone.
• Amorphous solid dispersions.
• Spray-dried or milled API systems.
• Lipid-based or self-emulsifying systems.
• pH-modifying excipient systems.
• Nanocrystal or particle-engineered febuxostat.

For a standard 40 mg or 80 mg tablet, these technologies may add manufacturing cost without producing a sufficiently large clinical or commercial benefit. They become more attractive when linked to a differentiated product claim, such as faster onset of urate lowering, reduced food sensitivity, lower tablet burden or an alternative dosage form.

What formulation patents protect Uloric and febuxostat products?

Uloric’s original U.S. exclusivity was based on the febuxostat active ingredient and related patent protection rather than a highly complex delivery system. The product received five-year new chemical entity exclusivity beginning with its 2009 approval, subject to the statutory framework applicable to the approval date. [1, 2]

The Orange Book should be used to confirm the current and historical listing status of Uloric patents, expiration dates and any pediatric exclusivity. Orange Book listings can include active-ingredient, formulation and method-of-use patents. Patent scope may differ materially from the inactive-ingredient list in the prescribing information. [2]

For commercial diligence, the relevant patent questions are:

1. Was the patent directed to febuxostat itself, a salt, a crystalline form, a composition or a method of treatment?
2. Did the patent cover the 40 mg and 80 mg dosage strengths?
3. Was the patent listed in the Orange Book at the time of generic filing?
4. Did any patent receive pediatric exclusivity or patent-term extension?
5. Did a generic applicant file a Paragraph IV certification?
6. Did litigation delay or shape generic launch timing?

A formulation developer should not assume that a non-lactose formulation avoids all patent risk. A patent may claim the active compound, a solid form, a composition range, a treatment method or a manufacturing process independently of the selected diluent.

When did Uloric lose exclusivity and when did generic febuxostat enter?

Uloric’s five-year NCE exclusivity period expired well before the current generic market. Generic febuxostat became commercially available in the United States after FDA approval of ANDAs and the resolution or expiry of relevant patent protections. The precise first-commercial-launch date and the set of first applicants should be confirmed from FDA approval records and Orange Book history before relying on them in a launch model. [2, 3]

The practical exclusivity timeline is:

Milestone	Timing
FDA approval of Uloric	February 2009
NCE exclusivity	Approximately five years from approval, subject to statutory rules
Major branded safety-label change	2019 boxed warning concerning cardiovascular death risk
Generic market formation	After relevant patent and regulatory barriers were cleared
Current market structure	Branded and generic febuxostat, with price pressure in standard tablets

The 2019 FDA safety communication and boxed warning changed the commercial positioning of febuxostat. FDA concluded that, in a required postmarketing safety trial, febuxostat was associated with a higher risk of cardiovascular death compared with allopurinol, although the FDA label also reflects the clinical context and limitations of the evidence. [4] This safety history may reduce the value of premium reformulation unless the product offers a credible adherence, tolerability or access benefit.

Which companies are challenging Uloric and febuxostat?

The competitive field includes generic manufacturers with ANDA approvals for febuxostat 40 mg and 80 mg tablets. Major generic participation has included companies such as Teva, Mylan or Viatris, Amneal and other FDA-approved suppliers, depending on the relevant product year and market status. Generic availability should be checked against the current FDA Drugs@FDA and Orange Book databases because approved products may be discontinued, transferred or listed as unavailable. [2, 3]

The main competitive categories are:

• Standard immediate-release febuxostat tablets.
• Authorized or branded-generic products.
• Low-cost institutional products.
• Potential 505(b)(2) reformulations.
• Non-U.S. febuxostat brands, including Adenuric in certain markets.

No biosimilar pathway applies. The competitive risk is therefore conventional generic erosion rather than interchangeability litigation characteristic of biologics.

What generic entry risks exist for a new febuxostat formulation?

The largest risk is that a new excipient system will not create sufficient differentiation from low-cost generic tablets. Standard febuxostat is already a mature oral solid dosage product, and generic manufacturers can often compete on price, supply reliability and pharmacy contracts.

A new product faces five primary risks:

1. Bioequivalence risk. Changes in particle size, disintegrant level, lubricant concentration or solubilization can alter exposure.
2. Dissolution risk. A formulation may pass the principal dissolution method but fail comparative profiles across relevant media.
3. Stability risk. Moisture-sensitive excipient systems can increase degradation or tablet softening.
4. Patent risk. New formulation claims may overlap active-ingredient, solid-form or method-of-use rights.
5. Commercial substitution risk. Payers may not reimburse a premium product when generic febuxostat is available.

A differentiated product should have a clear target product profile, such as lactose-free status, smaller tablet size, orally disintegrating delivery, improved swallowing, or a formulation designed for patients with difficulty taking conventional tablets.

What commercial opportunities exist for Uloric excipient innovation?

Lactose-free febuxostat tablets

This is the lowest-complexity opportunity. It could be implemented with mannitol, microcrystalline cellulose, calcium phosphate or co-processed excipients. The primary value is patient and pharmacy differentiation rather than strong intellectual property.

Orally disintegrating tablets

An orally disintegrating febuxostat tablet could address patients with dysphagia, older adults and patients receiving chronic polypharmacy. The principal technical challenges are taste masking, tablet robustness, moisture protection and rapid disintegration.

Taste masking may require polymer coating, ion-exchange resin complexation, lipid barriers or sweetener-flavor systems. The product must avoid excessive tablet mass and maintain acceptable mouthfeel.

Sprinkle or capsule-based delivery

A multiparticulate product could improve administration for patients who cannot swallow tablets. The dosage form would require data on dose uniformity, food administration, stability after opening and compatibility with soft foods. It may be more suitable for a 505(b)(2) strategy than for a conventional ANDA if the dosage form differs materially from the reference product.

Pediatric or geriatric liquid formulations

Febuxostat has limited routine pediatric use, so the addressable market is narrower than for common chronic medicines. A liquid could still have value in specialized populations, but preservative selection, pH control, sedimentation, dosing-device accuracy and chemical stability would materially increase development complexity.

Fixed-dose combinations

A febuxostat combination with another gout medicine could reduce pill burden, but the clinical and regulatory case is difficult. Allopurinol and febuxostat are generally alternative urate-lowering therapies rather than obvious co-administered actives. A combination with an anti-inflammatory or flare-management agent may also face questions about treatment duration, dosing flexibility and safety.

Sustainable excipient and packaging systems

A lower-impact product could use fewer coating materials, reduced solvent use, optimized tablet weight and recyclable packaging. Sustainability alone is unlikely to support a large price premium, but it can improve institutional procurement positioning when paired with supply reliability and cost control.

How strong is the febuxostat patent estate for an excipient-led product?

The patent strength of a new excipient formulation depends on claim specificity and clinical or pharmaceutical performance. Broad claims covering a tablet containing febuxostat and routine excipients are vulnerable to validity and obviousness challenges. Stronger protection may arise from:

• A defined solid form with reproducible advantages.
• A narrow dissolution or bioavailability profile.
• A specific particle-engineering process.
• A stable amorphous dispersion.
• A dosage form with clinically relevant administration benefits.
• A validated taste-masking or multiparticulate platform.
• A manufacturing process that materially improves impurity control.

The best commercial position is usually a layered estate: composition claims, process claims, dosage-form claims, and method-of-use claims where supported by data. A single lactose-free claim is unlikely to protect a product against routine substitution.

What is the FDA regulatory pathway for a differentiated febuxostat product?

A conventional tablet that matches the reference product in active ingredient, dosage form, strength, route and performance may qualify for an ANDA. A materially different dosage form, formulation, route, dosing regimen or labeling claim may require a 505(b)(2) application. FDA’s regulatory pathway depends on the extent of reliance on Uloric or another approved febuxostat product and the clinical data needed to support the change. [5]

The development pathway should align with the commercial claim:

Product concept	Likely regulatory issue
Lactose-free equivalent tablet	ANDA bioequivalence and pharmaceutical equivalence
New co-processed excipient tablet	ANDA if equivalence criteria are met
Orally disintegrating tablet	May require ANDA or 505(b)(2), depending on reference and performance
Sprinkle formulation	Often stronger 505(b)(2) rationale
Oral liquid	505(b)(2) risk increases because of dosage-form differences
Improved food-effect profile	Requires comparative pharmacokinetic evidence
New indication or dosing regimen	Requires method-of-use and clinical support

What litigation and settlement issues affect febuxostat?

Febuxostat litigation can involve active-ingredient patents, formulation patents, method-of-use patents, Paragraph IV certifications, ANDA filing dates and settlement terms. The commercial consequences include launch timing, possible 180-day exclusivity for a first filer, authorized-generic arrangements and restrictions on future formulations.

A complete transaction or launch analysis should review:

• Orange Book patent history.
• Paragraph IV notices.
• Hatch-Waxman complaints and case dockets.
• FDA tentative and final approvals.
• Any settlement or license agreements.
• Authorized-generic rights.
• Patent assignments and terminal disclaimers.

Public sources do not establish a single current settlement framework that governs every febuxostat product. Product-specific litigation review is required for any launch-date or freedom-to-operate conclusion. [2, 3]

How does Uloric compare with competing urate-lowering therapies?

Product	Active ingredient	Formulation opportunity	Competitive position
Uloric	Febuxostat	Lactose-free, ODT, sprinkle, improved dissolution	Genericized; safety warning limits premium positioning
Allopurinol	Allopurinol	Dose flexibility, renal-use positioning, combination concepts	Long-established, low-cost first-line competitor
Krystexxa	Pegloticase	Biologic infusion and immunogenicity management	Different patient segment; biosimilar complexity may emerge
Probenecid	Probenecid	Combination and adherence-oriented products	Older oral uricosuric alternative

Allopurinol is the main commercial comparator for routine gout management. FDA’s boxed warning for febuxostat affects prescriber behavior and may constrain premium pricing for an excipient-led product unless it solves a defined administration or adherence problem. [4]

What is the revenue exposure and launch opportunity?

The standard febuxostat tablet market is exposed to generic price erosion. Revenue potential is therefore more likely to come from niche positioning than from recreating Uloric’s original branded market.

The strongest commercial cases are:

1. A low-cost, lactose-free generic with reliable supply.
2. An orally disintegrating product for dysphagia and geriatric use.
3. A sprinkle or liquid product for patients unable to swallow tablets.
4. A branded-generic product with differentiated packaging and adherence support.
5. A specialty-channel product focused on renal or polypharmacy populations, subject to appropriate labeling and evidence.

A premium product should not rely solely on excipient novelty. It needs a measurable benefit in administration, adherence, tolerability, supply, or reimbursement.

Key Takeaways

• Uloric is febuxostat, a small-molecule xanthine oxidase inhibitor approved by FDA in 2009.
• The marketed tablet uses conventional excipients, including lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hydroxypropyl cellulose, colloidal silicon dioxide and magnesium stearate.
• The principal formulation challenge is controlling dissolution and bioequivalence for a weakly acidic, poorly soluble API.
• Lactose-free tablets are technically feasible but provide limited standalone patent strength.
• Orally disintegrating, sprinkle and liquid products offer stronger differentiation but increase regulatory and development complexity.
• Generic competition and the febuxostat cardiovascular boxed warning constrain premium pricing.
• No biosimilar pathway applies because febuxostat is a small molecule.
• ANDA is the likely pathway for an equivalent immediate-release tablet; materially different dosage forms may require 505(b)(2).
• A durable patent estate should combine formulation, process, dosage-form and supported method-of-use claims.
• Current Orange Book, FDA approval, litigation and market-availability records should control any launch, licensing or valuation decision.

FAQs

Can febuxostat tablets be manufactured without lactose?

Yes. Lactose can be replaced with excipients such as mannitol, calcium phosphate, starch-based fillers or co-processed materials, provided the formulation meets pharmaceutical-equivalence, dissolution, stability and bioequivalence requirements.

Is an orally disintegrating Uloric product likely to receive new market exclusivity?

Potentially, but exclusivity would depend on the regulatory pathway, the nature of the formulation change, any new clinical data and applicable patent claims. The dosage form alone does not guarantee meaningful exclusivity.

Does Uloric have biosimilar competition?

No. Febuxostat is a chemically synthesized small molecule. Competition is through generic ANDAs and, for differentiated products, potentially 505(b)(2) applications.

Can a febuxostat formulation patent cover only the excipients?

Yes, but narrow excipient-only claims are generally weaker than claims tied to a defined performance advantage, such as dissolution, stability, bioavailability, taste masking or a specific multiparticulate structure.

Is a febuxostat liquid commercially attractive?

It may be attractive for dysphagia and specialized populations, but the addressable market is narrower than for tablets. Preservative compatibility, chemical stability, dosing accuracy, packaging and 505(b)(2) requirements can materially increase development cost.

References

1. U.S. Food and Drug Administration. (2019). Uloric (febuxostat) prescribing information. FDA.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. FDA.
4. U.S. Food and Drug Administration. (2019, February 21). FDA adds boxed warning for increased risk of death with gout medicine Uloric (febuxostat). FDA.
5. U.S. Food and Drug Administration. (2020). Applications covered by section 505(b)(2). FDA.